Up Almost 2,000% in 2020, Is Vaxart Still a Buy?
In the race to develop vaccines against COVID-19, various pharmaceutical and biotech companies have made use of a number of innovative methods. Messenger-RNA vaccines. Electroporation devices that deliver DNA plasmid vaccines directly into patients' cells. And, in the case of Vaxart (NASDAQ: VXRT), a coronavirus vaccine that can be taken orally in tablet form.
Assuming that it eventually proves effective and passes regulatory muster, Vaxart's tablet could become one of the best ways to get people vaccinated in the developing world, where logistics are more difficult and healthcare providers have limited access to the cold storage facilities that the leading injectable vaccine candidates require.
With Vaxart stock up by around 1,980% year to date, is there still room for new investors to profit?
Source Fool.com
